SS-31 vs MOTS-c
Verdict: Both are 'mitochondrial peptides', but they work different problems. SS-31 (elamipretide) physically stabilizes cardiolipin on the inner mitochondrial membrane — think structural repair of the power plant — and has real human trials in rare mitochondrial diseases. MOTS-c is a mitochondrial-derived signaling peptide that acts like an exercise mimetic through AMPK — think metabolic tuning. Energy/healthspan protocols with an endurance flavor lean MOTS-c; interest in SS-31 tracks the clinical literature on mitochondrial dysfunction.
Side by side
| SS-31 | MOTS-c | |
|---|---|---|
| Typical dose | 5 mg–20 mg | 5 mg–10 mg |
| Frequency | daily or every other day | 1–3x weekly |
| Administration | subcutaneous injection | subcutaneous injection |
| Common vials | 10 mg, 50 mg | 5 mg, 10 mg |
| Typical mix | 10 mg + 2 ml water | 10 mg + 2 ml water |
| Units for typical dose | 200 units (10 mg) | 100 units (5 mg) |
Structure fixer vs signal sender
SS-31 concentrates on the inner mitochondrial membrane, binds cardiolipin and improves electron transport efficiency while reducing ROS leakage — mechanism validated across heart failure and mitochondrial myopathy trials, with mixed endpoint results. MOTS-c is encoded in mitochondrial DNA itself and translocates to the nucleus under stress, flipping on AMPK-driven metabolic programs: glucose uptake, fat oxidation, insulin sensitivity — hence the 'exercise in a vial' nickname in rodent literature.
Human data status
SS-31 is the rare research peptide with a genuine clinical program: elamipretide has been through phase 2/3 trials (Barth syndrome, primary mitochondrial myopathy, dry AMD). MOTS-c human data is a handful of small studies and observational exercise work; most excitement rests on mouse endurance and metabolic results.
Dosing patterns
Community protocols run MOTS-c 5–10 mg two to three times weekly, often cycled around training blocks. SS-31 reference dosing derives from trial infusion/injection regimens with daily milligram-level administration — expensive to replicate, which keeps it niche.
Can you stack them?
Complementary in theory — one repairs the machinery, the other tunes its output — and some longevity protocols run both with NAD+ support. Cost usually forces a choice, and MOTS-c wins on price per cycle.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.